Document Type

Article

Publication Date

9-8-2026

Comments

This article is the author’s final published version in Current Addiction Reports, Volume 13, Issue 1, 2026, Article number 79.

The published version is available at https://doi.org/10.1007/s40429-026-00786-4. Copyright © The Author(s) 2026.

 

Abstract

Purpose of Review Medetomidine is a veterinary α2-adrenergic agonist that has been an adulterant of illicitly manufactured opioids since 2022. We review its pharmacology, detection, intoxication, withdrawal, and management, and assess why severe withdrawal has emerged in some regions but not others. Recent Findings Medetomidine has spread through North American drug markets yet evades most toxicology testing. Roughly two hundred times more potent than xylazine, with greater α2 selectivity and imidazoline-1 activity, it causes intoxication resembling other α2 agonists: sedation and bradycardia. The dominant clinical problem is withdrawal: autonomic dysregulation, intractable vomiting, and encephalopathy frequently requiring intensive care. Treatment requires multimodal α2-agonist therapy, often escalating to parenteral dexmedetomidine. Where it is established, withdrawal encounters and hospital admissions have risen. Summary We hypothesize that both local prevalence and drug concentration determine where withdrawal appears. This syndrome exposes gaps in both assessment and treatment; prospective multicenter research, a validated withdrawal instrument, and integrated addiction-critical care models are needed.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Language

English

Download

Share

COinS